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Abstract
Background Achievement of complete surgical resection
plays a key role in the successful treatment of children with
hepatoblastoma. The aim of this study is to assess the
surgical outcomes after partial liver resections for hepato-
blastoma, focusing on postoperative complications, resec-
tion margins, 30-day mortality, and long-term survival.
Method Chart reviews were carried out on all patients
treated for hepatoblastoma in the Netherlands between
1990 and 2013.
Results A total of 103 patients were included, of whom 94
underwent surgery. Partial hepatectomy was performed in
76 patients and 18 patients received a liver transplant as a
primary procedure. In 42 of 73 (58 %) patients, one or
more complications were reported. In 3 patients,
information regarding complications was not available.
Hemorrhage necessitating blood transfusion occurred in 33
(45 %) patients and 9 (12 %) patients developed biliary
complications, of whom 8 needed one or more additional
surgical interventions. Overall, 5-year disease-specific
survival was 82, 92 % in the group of patients who
underwent partial hepatectomy, and 77 % in the group of
patients who underwent liver transplantation.
Conclusions Partial hepatectomy after chemotherapy in
children with hepatoblastoma offers good chances of sur-
vival. This type of major surgery is associated with a high
rate of surgical complications (58 %), which is not detri-
mental to survival.
Keywords Hepatoblastoma  Partial hepatectomy 
Postoperative complications  Hemorrhage  Biliary
complications
Introduction
Hepatoblastoma is the most common malignant liver tumor
and the third most common intra-abdominal neoplasm in
children in Western countries. Overall, survival has sig-
nificantly improved from 35 to 83 % over the last four
decades due to advances in chemotherapy [1–5]. Complete
surgical resection remains essential in the successful
treatment for children with hepatoblastoma.
In adults, partial liver resections are associated with high
complication rates, but in children, little is known about
this topic [6]. Morbidity rates between 22 and 49 % have
been shown in literature and potential complications
include hemorrhage, biliary leakage or obstruction, infec-
tion, liver failure, and tumor positive resection margins
[1, 7–13]. A better insight into the surgical outcomes and
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complications of partial liver resections could improve
outcome and reduce morbidity.
The aim of this study was to give an overview of the
experience with the surgical treatment of children with
hepatoblastoma in the Netherlands between 1990 and 2013.
This study focuses on the (surgical) treatment of the pri-
mary liver tumor. However, since the occurrence and
management of distant metastases play an important role in
the treatment for children with hepatoblastoma, this subject
will be addressed in a less extensive manner.
Methods
Patients
A retrospective chart review was performed on all children
treated for hepatoblastoma in one of the Pediatric Surgical
Oncology Centers in the Netherlands between 1990 and
2013. These hospitals were the only national tertiary cen-
ters responsible for the treatment of hepatoblastoma in
patients under the age of 18 years. Patient charts and sur-
gical reports were used to collect information, regarding
demographics, tumor characteristics, diagnostic tests, sur-
gical treatment, postoperative morbidity (in the case of
partial liver resection), mortality, and follow-up. Children
were excluded from analysis if the histopathology report
after resection or transplantation resulted in a diagnosis
other than hepatoblastoma.
Investigation methods
Ultrasonography, chest radiography, and alpha-fetopro-
tein (aFP) levels in the blood were the first diagnostic
tools used in all children with a suspicious abdominal
mass. The diagnosis was made according to the Inter-
national Childhood Liver Tumors Strategy Group
(SIOPEL) protocols running at that time (SIOPEL 1–4)
[1, 4, 14–16]. This included a pre-operative tumor
biopsy according to SIOPEL 4, which was not manda-
tory for children between 6 months and 3 years with a
solid hepatic mass and elevated serum aFP in SIOPEL
1–3. However, following the results of a Dutch study
published in 2005, this was already promoted as a part
of standard care [17].
Before starting with neoadjuvant chemotherapy, a
computed tomography (CT) or Magnetic Resonance
Imaging (MRI) scan was performed to evaluate tumor
extension and involvement of vessels and other intra-ab-
dominal organs. The PRETEXT system (PRE Treatment
EXTent of disease staging system) was used for staging
and risk stratification [18]. In addition, a CT scan of the
chest was made to detect possible pulmonary metastases.
Tumor response and resectability after neoadjuvant
chemotherapy were evaluated using either CT scan or MRI.
Pre-operative treatment
SIOPEL guidelines for the treatment of liver tumors in
children were introduced in the Netherlands in the early
1990s. Since then, chemotherapy regimen consisted of a
combination of cisplatin, doxorubicin, and carboplatin,
according to SIOPEL 1–4 studies [1, 4, 14–16]. Before the
introduction of these guidelines, patients received
chemotherapy according to locally developed protocols.
Surgical treatment
Primary tumor
Patients were treated in one of the pediatric surgical centers
in the Netherlands experienced in liver resections after
treatment with neoadjuvant chemotherapy. Surgical treat-
ment strategies were based on SIOPEL 1–4 protocols
running at the time of diagnosis [1, 4, 14–16]. Standard
surgical techniques for tumor resection were used [19].
During surgery, ultrasonography was used when consid-
ered necessary. If the primary tumor was considered
unresectable after neoadjuvant chemotherapy, primary
orthotopic liver transplantation was performed. Liver
transplantation was indicated in the case of extensive
(multifocal) disease (PRETEXT IV) or in the case of an
unifocal centrally located tumor involving the main hilar
structures or the main hepatic veins (SIOPEL 1–4) [20].
Transplantation was performed in a specialized transplant
center. The vast majority of these transplantations were
performed abroad.
Metastatic disease
If pulmonary metastases were still present after treatment
with chemotherapy, metastasectomy [via sternotomy, tho-
racotomy or video assisted thoracoscopic surgery (VATS)]
was performed whenever possible. This procedure was
usually performed after complete removal of the primary
liver tumor, except in candidates for liver transplant, who
had to be free from metastases before liver surgery.
Postoperative complications
Information regarding postoperative complications after
partial hepatectomy was used for analysis. Complications
were defined as any deviation from the normal postopera-
tive course. The following definitions were used:
Hemorrhage Perioperative bleeding necessitating blood
transfusion or re-operation.
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Infection Any type of infection related to the surgical
procedure necessitating the use of antibiotics or drainage
(open or percutaneous) of abscesses.
Biliary complications Bile leak and/or a biliary tract
stricture.
Vascular complications Compromised hepatic blood
flow due to the surgical procedure.
Other Any other postoperative complications related to
the surgical procedure requiring re-intervention and/or
prolonged hospital stay.
Follow-up
All patients were followed-up at children’s oncology out-
patient clinics.
aFP levels were determined and chest X-rays and
abdominal ultrasonography were performed to monitor
recurrence according to SIOPEL-protocols.
Statistical analysis
Patient, tumor, and treatment characteristics were descri-
bed using frequency tables. Disease-specific survival was
calculated from the date of diagnosis until date of death
(related to hepatoblastoma) or last follow-up. Patients who
died due to other causes (not related to hepatoblastoma)
were censored. Disease-specific survival was analyzed
using the Kaplan–Meier survival analysis with a 95 %
confidence interval (CI). Median follow-up time was ana-
lyzed using a reverse Kaplan–Meier method. A p value
\0.05 was considered statistically significant. Statistical
analyses were performed in the PASW Statistics version 21
(SPSS inc., Chicago, IL, USA).
Results
Clinical features
Between 1990 and 2013, a total of 103 children were
treated for hepatoblastoma in the Netherlands. Patient and
tumor characteristics are shown in Table 1.
Surgical treatment
Primary tumor
Nine (9 %) patients died before surgery was performed,
due to progressive disease under therapy. Eighteen (17 %)
patients underwent total hepatectomy combined with
orthotopic liver transplantation as a primary procedure and
76 (74 %) patients underwent a partial liver resection
(Fig. 1). Table 2 gives an overview of the different surgical
procedures performed. Thirty-four (45 %) patients under-
went an extended hemihepatectomy, while in 10 (13 %)
patients, partial liver resection was combined with several
additional procedures.
Metastatic disease
Figure 2 shows the 28 patients diagnosed with metastatic
disease (synchronous and metachronous). Seven of the
twenty-two patients eligible for surgery with curative intent
Table 1 Patient and tumor characteristics
Category Number (%)
Gender
Male 62 60
Female 41 40
Age (months)
Median 15 –
Range 0–162 –
AFP (lg)
Mean 432.614
Median 210.000
Range 15–380.400.0
PRETEXT
I 4 3.9
II 25 24
III 26 25
IV 20 19
Missing 28 27
Tumor location
Right 68 66
Left 8 8
Bilateral 20 19
Unknown 7 7
Histopathology
Epithelial 30 29
Epithelial/mesenchymal 39 38
Mesenchymal 1 0.9
Not specified 33 32
Local disease 75 73
Metastatic disease 28 27
Pulmonary 27
Pulmonary, spleen, pancreas 1
Type of liver tumor
Unifocal 80 78
Multifocal 23 22
Follow up (months)
Median 61 –
Range 0–213 –
PRETEXT pretreatment extent of disease
Pediatr Surg Int
123
had surgical resection of lung metastasis at varying times in
their treatment. In three patients, metastasectomy was
performed after surgical treatment of the primary liver
tumor, and in three patients, this took place before primary
tumor removal. Two of the latter patients eventually
underwent total hepatectomy and primary liver transplan-
tation. The third patient, initially planned for primary liver
transplantation, responded well to chemotherapy and par-
tial liver resection was performed successfully. In one
patient, no information about metastasectomy was avail-
able. No metastases were resected simultaneously with
liver resection.
Surgical outcomes after partial liver resection
Resection margins
Of 76 patients who underwent partial liver resection, the
pathology report showed complete tumor removal in 66
(87 %) patients and microscopic tumor residue in 2 (3 %)
patients. In 5 (7 %) patients, results were inconclusive
which was followed by expectative treatment. In 3 (4 %)
patients, there was no information about resection margins.
None of the 10 patients with microscopic tumor residue or
Fig. 1 Overview of the surgical treatment of patients with hepato-
blastoma in the Netherlands (1990–2013)
Table 2 Overview of surgical
procedures primary tumor
Number %
Primary liver transplantation 18 19
Partial liver resection 76 81
Segmentectomy 10
Hemihepatectomy, left sided 12
Hemihepatectomy, right sided 19
Extended hemihepatectomy, left sided 2
Extended hemihepatectomy, right sided 32
Other, removal of pedunculated tumor 1
Partial liver resection combined with 10
Partial resection diaphragm 1
Partial resection diaphragm ? cecal pole resection 1
Reconstruction inferior vena cava and left hepatic vein 1
Right sided adrenalectomy ? additional segmentectomy 1
Additional segmentectomy 3
Resection portal vein 2
Roux-en-Y hepaticojejunostomy 1
Fig. 2 Overview of the surgical treatment of metastatic disease in patients with hepatoblastoma in the Netherlands (1990–2013)
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missing or inconclusive data about resection margins pre-
sented with recurrent disease during follow-up.
Postoperative complications
Three patients without information about complications
were, therefore, excluded from further analysis. In 42
(58 %) of 73 patients, one or more complications were
reported. In total, 52 complications were registered
(Table 3). Among the patients who experienced a com-
plication, 43 % were staged PRETEXT III or higher,
compared to 32 % in the group without a complication
(p = 0.535) (Table 4).
Hemorrhage Thirty-three (45 %) patients received a
blood transfusion because of perioperative hemorrhage.
None of them required additional surgery. However, one of
these patients (a 15-month-old infant with 1800 cc blood
loss) needed cardiopulmonary resuscitation (CPR) due to
hemodynamic instability on the second day after surgery.
Infection In 6 (8 %) patients, a postoperative infection
was reported, including two central venous line (CVL)
infections/sepsis leading to removal of the line, an infected
hematoma which required an additional laparotomy, and a
wound infection and subsequent wound dehiscence and
evisceration which required additional surgery. In two
patients with infected ascites and clostridium enterocolitis,
no additional surgery was needed.
Biliary complications Nine of seventy three (12 %)
patients who underwent a partial hepatectomy experienced
biliary complications. Eight patients developed a bile
leakage and one patient developed cholestasis due to a
biliary stricture. Eight of nine patients experiencing prob-
lems with biliary drainage needed one or more additional
interventions (median 3; range 1–22 procedures) to resolve
the biliary complication. These procedures included per-
cutaneous biliary drainage of a biloma with or without
leaving a drain in situ, endoscopic retrograde cholan-
giopancreatography (ERCP) with sphincterotomy, with or
without biliary stenting, and percutaneous hepatic cholan-
giography (PTC) with biliary drainage and Roux-en-Y
hepaticojejunostomy. In the remaining patient, problems
resolved spontaneously.
Vascular complications Two (3 %) patients who
underwent partial liver resection developed postoperative
problems with hepatic blood flow. The first patient under-
went a partial liver resection combined with a reconstruc-
tion of the caval- and left hepatic vein due to tumor
ingrowth. Eventually, this patient developed the Budd–
Chiari Syndrome with portal hypertension and liver cir-
rhosis. This resulted in multiple surgical procedures and
eventually led to liver transplantation 9 years after the
initial liver resection.
The second patient developed postoperative liver func-
tion problem due to thrombosis of the portal and left
hepatic vein. Surgical revascularization and percutaneous
thrombectomy were unsuccessful, and eventually, this
patient received a liver transplant 7 days after the initial
liver surgery with good outcome.
Other One patient with delayed gastric emptying needed
a duodenal feeding tube that had to be placed under general
anesthesia. In one patient, ECG abnormalities were repor-
ted during surgery, most likely due to an air embolism.
Postoperative mortality
No early deaths (within 30 days) were reported after partial
hepatectomy.
However, one patient with pulmonary metastases died
within 30 days after metastasectomy. This patient devel-
oped respiratory insufficiency due to persistent air leakage
after extensive pulmonary surgery. Re-thoracotomy could
not resolve the leakage.
Recurrent disease
Sixteen (17 %) of the ninety four patients eligible for
surgery with curative intent presented with recurrent dis-
ease. In three patients, recurrent disease was diagnosed
Table 3 Perioperative complications and additional procedures
Type of complication Number/surgical
proceduresa
Hemorrhage requiring transfusion 33/0
Infection (CVL/sepsis/wound/hematoma/ascites) 6/2
Biliary complications (bile leakage/cholestasis) 9/8
Vascular complications 2/2
Other 2/1
CVL central venous line
a Number of patients receiving additional surgery due to
complication
Table 4 Staging and postoperative outcomes after partial
hepatectomy
Stage With complications
(n = 42)
Without complications
(n = 31)
Number Number
PRETEXT 1 1 2
PRETEXT 2 13 11
PRETEXT 3 15 (3a) 6
PRETEXT 4 3 4
Unknown 10 (1a) 8
PRETEXT pretreatment extent of disease
a Number of patients died of disease
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after primary total hepatectomy and transplantation, and in
13 patients, recurrent disease was diagnosed after partial
liver resection. Details of management and outcomes of
these 16 patients are shown in Fig. 3.
Local
Two patients who underwent partial hepatectomy pre-
sented with recurrent disease involving the liver. One of
these patients underwent rescue transplantation and the
other patient died because of progressive disease.
In one patient, recurrent disease was found at the entry
site of the intra-abdominal drain placed post operatively
(drain site metastasis). The tumor was successfully
removed.
Distant
Figure 3 shows that in 6 of 12 patients diagnosed with dis-
tant relapse, a second complete remission could be achieved
after metastasectomy. At the time of analysis, one patient
with pulmonary relapse was alive with recurrent disease.
Three patients with pulmonary relapse and one patient with
both pulmonary relapse and retroperitoneal lymph node
metastases died because of progressive disease. One patient
was lost to follow-up. Six patients with distant relapse were
initially diagnosed with pulmonary metastases (Fig. 2).
Both
One patient developed both local and pulmonary recur-
rence. Further curative treatment was felt to be futile.
Survival
All but one death were related to progressive disease or due
to relapse of the primary tumor. One patient was diagnosed
with an intra-abdominal desmoid tumor and died. Figure 4
shows results for disease-specific survival for different
groups. Overall, 5-year survival was 82 % (95 % CI
74–89). In the group of 76 patients who had a partial
hepatectomy, 5-year survival was 92 % (95 % CI 86–98).
Table 4 shows that among the five patients who eventually
died after partial hepatectomy, four patients experienced
one or more postoperative complications. Three of these
patients were staged PRETEXT 3, and in two patients,
staging was not documented. In one patient, there was no
information about complications (therefore, not shown in
Table 4). Of 18 patients who had primary transplantation,
the 5-year survival was 77 % (95 % CI 58–97) (Fig. 4).
Discussion
Partial hepatectomy for hepatoblastoma in children is a
complex procedure, but essential for the cure of this dis-
ease. The results of this study show that partial hepatec-
tomy in this group of patients is associated with high
complication rates (58 %). However, a large proportion of
these complications were considered minor and 5-year
survival rates are good (92 %).
In 45 % of the patients who underwent a partial liver
resection, a blood transfusion was required. This corre-
sponds with high rates (57 %) of red blood cell transfusion
found by Tannuri et al. after hepatic resections in children
Fig. 3 Management and outcomes for hepatoblastoma patients with relapsed disease (1990–2013)
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with an estimated blood loss between 50–2000 mL (mean
blood loss 280 mL) [9]. Compared with adults, total blood
volume is relatively small in pediatric patients. In this
study, the median age at time of diagnosis was 15 months,
which corresponds with mean circulating volume of
800–1000 mL. Young children do not tolerate blood loss as
well as adults. Therefore, even a minor blood loss may
necessitate transfusion. In adults, perioperative bleeding
during partial hepatectomy is a common complication with
higher incidence of liver failure and a shorter long-term
survival [21, 22]. There are no studies that support these
findings in children. None of our patients needed a surgical
re-intervention because of bleeding, but one needed CPR.
The other patients could be treated with blood transfusion
only. In our study, there was no association between blood
loss and outcome after surgery, but the numbers of patients
are relatively small.
Results of this study show that 12 % of the patients
developed biliary complications, and all but one needed
one or more additional interventions to correct the under-
lying problem. Biliary complications after partial liver
resection occur in 5–29 % of the children [11, 12, 17, 23].
If the injury is recognized during the surgical procedure, it
can be repaired immediately. However, if biliary compli-
cations present after surgery, they are difficult to manage
and often require additional surgery [12]. Results of a study
by Steen et al. suggested that relatively high rates of biliary
complications after partial liver resection in children might
be associated with a high percentage of patients who
received neoadjuvant chemotherapy [11]. The results of
this study do not support this hypothesis, since the overall
biliary complication rates were relatively low and all
patients included in this study received neoadjuvant
chemotherapy before undergoing partial liver resec-
tion. Furthermore, the results of the SIOPEL-1 study
showed that neoadjuvant chemotherapy leads to down-
staging of the tumor and results in a less extensive liver
resection in 25 % of the cases [1]. In addition,
chemotherapy makes the tumor mass less prone to bleeding
and better demarcated from the surrounding normal hepatic
parenchyma, resulting in a safer and complete tumor
resection [5]. Other possible explanations for developing
more biliary complications, such as patient characteristics,
and operative technique and surgeon experience should be
further investigated.
Post-resection liver failure is a devastating complication
that sometimes follows partial hepatic resection. In adults,
the reported incidence of post-resection liver failure ranges
between 0 and 32 % [24, 25]. This percentage may be
lower in children, since most children have no underlying
parenchymal liver disease influencing liver function and
usually show excellent hepatic regeneration and return of
function after hepatic resection [26, 27]. However, there
are no large studies to support this. In children, resection of
80 % of the liver mass can be accepted after treatment with
toxic agents [26]. To avoid long-term side effects of
immunosuppressive therapy after transplantation, surgeons
might extend criteria in favor of resection rather than
transplantation in patients with extensive disease [28, 29].
Nonetheless, inadequate quantity or quality of residual
liver mass remains a potential cause of liver failure and
may require additional transplantation. Therefore, central
review and surgical management at institutions experi-
enced in both advanced pediatric hepatobiliary surgery and
transplantation is essential for these children [28, 29]. In
this study, two patients needed rescue transplantation after
partial liver resection because of liver failure. In both
patients, this was due to vascular complications after par-
tial liver resection and not because of inadequate quantity
or quality of the residual parenchyma. Both patients were
still alive after 1 and 11 years of follow-up, respectively.
Once complete remission has been achieved, relapse is
relatively rare (\12 %) [30] [31]. Prognostic factors for
failure of the treatment of hepatoblastoma include the
presence of metastasis, large tumor mass (high PRETEXT
stage), age, small cell undifferentiated histology, and the
aFP level at presentation [31]. In most patients, recurrent
disease presents with rising levels of aFP [30]. Relapses
can be local, metastatic, or combined. In this study, 16
patients (17 %) had recurrent disease; 3 patients presented
with local recurrence, 12 with pulmonary relapse, and 1
patient with both local and distant relapse. Six out of
twelve patients with pulmonary relapse were initially
Fig. 4 5-year disease specific survival for patients with hepatoblas-
toma (n = 103), after partial hepatectomy (n = 76), after total
hepatectomy and transplantation for patients with hepatoblastoma
(n = 18) in the Netherlands (1990–2013)
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diagnosed with pulmonary metastasis and only one of these
patients underwent metastasectomy. Therefore,
chemotherapeutic failure rather than inadequate metasta-
sectomy is a more likely cause of relapse. The place of
more aggressive surgery in this group remains to be
elucidated.
Once relapse occurs, a second remission can be
achieved by treating the patient with chemotherapy, com-
bined with surgical resection of the tumor mass. For pul-
monary relapses, resection of the tumor by means of
thoracotomy provides long-term cure in only 30 % of the
cases [32, 33]. In this study, 6 of 12 (50 %) patients with
pulmonary relapse survived (Fig. 3). In total, 6 (38 %) of
16 patients with relapsed disease survived. One patient was
alive with recurrent disease and one patient was lost to
follow-up.
Due to the retrospective character of this study,
together with the long time period included in this study
(24 years), retrievability of the data was challenging,
especially for patients who underwent treatment in the
pre digital period. For PRETEXT stage and tumour
location, we restricted ourselves to patients’ charts and
we did not review old films. The challenges addressed
above makes the case for prospective data collection
even stronger and we advocate inclusion of surgical data
in the SIOPEL analysis.
Centralization of these high-complex and low-volume
procedures could potentially lead to further improvement
of surgical technique and perioperative care and might
have a beneficial effect on postoperative outcomes and
survival as shown for other high complex (pediatric) sur-
gical procedures [34–36]. Further research is necessary,
since the effects of caseload and organization of care on
outcomes for patients with hepatoblastoma have not yet
been investigated.
Conclusion
In conclusion, this study shows that partial liver resection
after chemotherapy in children with hepatoblastoma offers
good chances of survival, even after pulmonary relapse.
The results of this study show that partial hepatectomy in
this group of patients is associated with high complication
rates (58 %). However, a large proportion of these com-
plications were considered minor. Four patients died after
partial hepatectomy of local or distant relapse and this was
never attributable to operative or postoperative
complications.
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